'Earlier in April, we initiated the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 pivotal trial evaluating a fixed-dose combination of sulbactam plus durlobactam, or SUL-DUR (ETX2514SUL), as a potential treatment for carbapenem-resistant
Acinetobacter baumannii infections.
"Earlier in April, we initiated the global ATTACK Phase 3 pivotal trial evaluating a fixed-dose combination of sulbactam plus durlobactam, or SUL-DUR, as a potential treatment for carbapenem-resistant
Acinetobacter baumannii infections.
Pseudomonas aeruginosa,
Acinetobacter baumannii ve Klebsiella pneumoniae gibi cok ilaca direncli Gram-negatif bakterilerin son yillarda artmasi sebebiyle bu ilaca olan gereksinim de giderek artmaktadir.
NDM-1 producing
Acinetobacter baumannii isolated from a patient repatriated to the Czech Republic from Egypt, July 2011.
Recently, the World Health Organisation listed drug-resistant
Acinetobacter baumannii to be a critical priority pathogen, causing around 9% of all bacterial infections in intensive care worldwide, against which there are few treatment options available.
Acinetobacter baumannii, a major source of nosocomial infections, is no exception, and 2 MLST schemes (Oxford and Pasteur) have been established for this species (3,4).
Acinetobacter baumannii is an encapsulated, catalase-positive, non-motile, Gram-negative coccobacilli bacterium (1).
The New Jersey Department of Health learned late Monday that two premature infants with confirmed cases of
Acinetobacter baumannii died last week in the neonatal intensive care unit at University Hospital in Newark.The New Jersey Department of Health learned late Monday that two premature infants with confirmed cases of
Acinetobacter baumannii died last week in the neonatal intensive care unit at University Hospital in Newark.
Acinetobacter baumannii is an aerobic, non-motile gram negative bacillus and an important cause of hospital acquired infections.
Increase of carbapenem-resistant
Acinetobacter baumannii infection in acute care hospitals in Taiwan: Association with hospital antimicrobial usage.
Acinetobacter baumannii (ACB) has been considered a worrisome bacterial agent associated with hospital-acquired infections (HAI), mainly in developing countries.
(0.9%) and 1
Acinetobacter baumannii (0.9%) were the other pathogen isolations in the groups obtained at different times (TABLE I).
